What is Insulet Corporation (PODD) DCF Fair Value and Intrinsic Value in 2026?

Insulet Corporation (PODD) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Insulet Corporation's historical Return on Invested Capital (ROIC) and Moat Rating?

Insulet Corporation operates in the Healthcare sector (Medical Devices) with an economic moat rating of WIDE. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Insulet Corporation's financial health rating and Piotroski F-Score?

Insulet Corporation's balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Insulet Corporation (PODD) for quarterly SEC filing thesis breaks?

LocalAlpha audits Insulet Corporation's 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksPODD

PODD

Insulet CorporationHealthcare / Medical DevicesINTACT

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Share Price

$145.89

52W: $126.4 - $354.88

DCF Fair Value

$33.50

-335.5% Premium

Thesis Hub

P/E (TTM)

23.8x

ROIC

16.9%

Operating Margin

22.5%

FCF Yield

1.1%

Debt / Equity

0.66x

Piotroski Score

8/9

Altman Z-Score

3.57

Market Cap

$10.1B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($33.50)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$33.50

MOS Buy Target (-25%)

$25.13

Valuation Overlays: DCF Fair Value ($33.50) 25% MOS Buy Target ($25.13) Revised Graham ($142.49) Graham Number ($55.99)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$145.89

DCF Fair Value

$34.52

-322.6% Premium

Starting Free Cash Flow ($M)$114M

$100M$114M (Reported)$50,000M

Stage 1 Growth (Years 1-5)11.3%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$400M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$1.2B

PV of Terminal Value

$1.6B

Implied Enterprise Value

$2.8B

Implied Equity Value

$2.4B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$127	$141	$157	$175	$195	$203	$213	$222	$232	$243
Present Value (PV)	$116	$119	$121	$124	$127	$121	$116	$112	$107	$102

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-160.6% Premium

$55.98

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $6.12BVPS: $22.76

Revised Graham Formula-2.4% Premium

$142.49

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings1.1% Yield

$1.57 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.1BYield: 1.1%

Reverse DCF: Market Growth Expectation

SPECULATIVE BARRIER

25.5% CAGR (Next 10 Yrs)

At the current price of $145.89, the market is assuming the business will compound Free Cash Flow at 25.5% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

⚠ High expectations: Leaves minimal margin of safety for operational hiccups.

Autonomous Thesis Underwriting

Surveil PODD with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Insulet Corporation. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 22.5% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track PODD & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Insulet Corporation (PODD) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Insulet Corporation.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Insulet Corporation has an estimated DCF intrinsic fair value of $33.50 per share compared to its current market price of $145.89. This represents an estimated 335.5% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $55.99.